Seock-Ah Im

57PUBLICATIONS
363CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Ngā pūtaiao koiora-hauora, haumanu hoki o te Māori (Māori biomedical and clinical sciences)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (57)

|Jun 08, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

|May 26, 2026
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Juanita S Lopez, Kevin J Harrington, Seock-Ah Im

|Mar 28, 2026
Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.

Yoonjin Kwak, Tae-Yong Kim, Hye Seung Lee

|Feb 17, 2026
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Ben Tran, Mark Voskoboynik, Sang-We Kim

|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

Pageof 10

Frequent Collaborators

10 joint publications

Kyung-Hun Lee

8 joint publications

Nadia Harbeck

8 joint publications

Hope S Rugo

7 joint publications

Tae-Yong Kim